<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00845117</url>
  </required_header>
  <id_info>
    <org_study_id>EC 7/28/153</org_study_id>
    <nct_id>NCT00845117</nct_id>
  </id_info>
  <brief_title>Cultivated Stem Cell Transplantation for the Treatment of Limbal Stem Cell Deficiency</brief_title>
  <acronym>LECT</acronym>
  <official_title>Cultivated Stem Cell Transplantation for the Treatment of Limbal Stem Cell Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ethisch Comité UZ Antwerpen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fund for Scientific Research, Flanders, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Society of Cataract and Refractive Surgeons</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agentschap voor Innovatie door Wetenschap en Technologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether cultivated stem cell transplantation is
      effective for the treatment of patients wtih corneal stem cell deficiency.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>Just before surgery and upto 1 years after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctivalization</measure>
    <time_frame>Just before surgery and upto 1 years after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascularization</measure>
    <time_frame>Just before surgery and upto 1 years after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Epithelialization</measure>
    <time_frame>Just before surgery and upto 1 years after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prolonged subsequent corneal graft survival time</measure>
    <time_frame>1 year post corneal transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Limbal Stem Cell Deficiency</condition>
  <arm_group>
    <arm_group_label>Limbal Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The cornea is debrided of all superficial fibrovascular tissue and the cultivated stem cell graft is glued onto the cornea.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cultivated limbal stem cell graft transplantation</intervention_name>
    <description>A limbal biopsy taken from the contralateral good eye in cases of unilateral disease or from a living related or cadaveric donor in cases of bilateral disease. The limbal stem cells from the biopsy are cultivated until a sheet of cells measuring approximately 12mm in diameter is obtained. This is then ready for transplantation onto the diseased eye.</description>
    <arm_group_label>Limbal Stem Cell Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering from LSCD IIa and IIb. Those suffering from IIc may be included
             once inflammation has subsided and cornea can be staged as IIb.

          -  Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before registration in the trial.

          -  Women of child-bearing potential should use adequate contraception prior to study
             entry and for the duration of study participation

        Exclusion Criteria:

          -  Subjects who are pregnant or lactating

          -  Subjects who have sensitivity to drugs that provide local anesthesia

          -  Subjects suffering from active infection of the external eye

          -  Medical conditions that prohibit the use of systemic immunosuppression (in cases of
             allogenic transplantation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadia Zakaria, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carina Koppen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie J Tassignon, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zwi Berneman, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Antwerp</city>
        <state>Edegem</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Zakaria N, Koppen C, Van Tendeloo V, Berneman Z, Hopkinson A, Tassignon MJ. Standardized limbal epithelial stem cell graft generation and transplantation. Tissue Eng Part C Methods. 2010 Oct;16(5):921-7. doi: 10.1089/ten.TEC.2009.0634.</citation>
    <PMID>19916804</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2009</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Ethisch Comité UZ Antwerpen</investigator_full_name>
    <investigator_title>Prof. Dr. Marie-Jose Tassignon</investigator_title>
  </responsible_party>
  <keyword>Aniridia,</keyword>
  <keyword>Steven Johnsons Syndrome,</keyword>
  <keyword>Ocular burns,</keyword>
  <keyword>Pterygium</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

